ArticleLeukemia2026

Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.

Anthony G Mansour et al.PubMed ↗Publisher ↗

No numbers read from the abstract.